ReviewJournal of translational medicine2025
Radiology-based artificial intelligence for predicting targeted therapy response in pan-cancer: a comprehensive review.
Review in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A bibliometric analysis of artificial intelligence in ovarian cancer research from 2006 to 2025.Discover oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTargeted therapy is central to precision oncology, but identifying patients who will benefit remains challenging. Conventional molecular testing, though the current standard, provides limited predictive value. With recent advances in artificial intelligence (AI) and the widespread availability of imaging data, radiology-based AI models have emerged as valuable non-invasive tools for treatment response assessment.
methodsWe conducted a comprehensive review of 112 studies that developed radiology-based AI models for predicting responses to targeted therapy across various cancer types. The reviewed models were classified into direct prediction approaches, which use end-to-end imaging-based modeling to estimate therapeutic response, and indirect prediction approaches, which infer molecular biomarkers from imaging features to indirectly assess therapeutic sensitivity.
resultsAcross the identified literature, computed tomography (CT) was the most frequently used imaging modality, followed by magnetic resonance imaging (MRI), positron emission tomography (PET), and ultrasound (US). Lung and breast cancers were the most commonly studied diseases, though work has also expanded into gastric, colorectal, liver, kidney, brain, and ovarian cancers. Both machine learning (ML) and deep learning (DL) frameworks have been applied, with ML remaining dominant but DL gaining increasing attention in recent years, likely because ML offers interpretability and suitability for smaller datasets, whereas DL excels in handling complex, high-dimensional data. Collectively, these studies demonstrate promising performance in predicting response to targeted therapy, while also highlighting the diversity of cancer contexts and methodological designs.
conclusionRadiology-based AI offers a non-invasive approach to guide treatment selection and monitoring in targeted therapy. This review summarizes current progress, highlights strengths and limitations of direct and indirect prediction strategies, and discusses future directions. To support accessibility, we also provide a continuously updated interactive website of included resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.